ReviewAdvances in experimental medicine and biology2025
Development of Automated Systems for Cell Therapy.
Review in Advances in experimental medicine and biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The introduction of automated systems that can increase manufacturing efficiency and eliminate human errors is indispensable for the dissemination of cell therapy. However, a robotic operation without process monitoring and manufacturing records needs a "verification" process at the end of manufacturing for each shipment, just like manual operation would have required, which is called the Pharma 3.0 manufacturing stage, and would not visualize the manufacturing process nor link with inventory control. A simple robotic system that can mimic human operation will not contribute to innovation in the cell manufacturing industry. Here we show the quality by design (QbD)-based automated closed-type cell manufacturing system with in-process monitoring that could eliminate a "verification" process prior to shipment and assure the quality of the product by manufacturing the product as designed, which will contribute to the industrialization of cell manufacturing that can support the dissemination of cell therapy.
Indexed as
Identifiers
41136839What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.